Symposium:
165. Hot Topics in STIs
Saturday, October 5, 2013: 10:30 AM-12:00 PM
Room: The Moscone Center: 103 (Gateway Ballroom)
Co-organized with the American Sexually Transmitted Diseases Association

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • summarize new directions in treatment and prevention of sexually transmitted pathogens
  • describe the utility of nucleic acid amplification test for detecting rectal and pharyngeal gonococcal and chlamydial infections
  • review current evidence supporting the pathogenic nature of Mycoplasma genitalium and approaches to treatment
  • discuss controversies surrounding the determination of need for lumbar puncture to diagnose neurosyphilis, and approaches to treatment and follow-up

Target Audience: public health practitioners, members-in-training, infectious diseases physicians, infectious diseases pediatricians, fellows, clinicians, academicians

Tracks: HIV-STD-TB, Adult ID

Moderators:  Gail Bolan, MD, Centers for Disease Control and Prevention and Bradley P. Stoner, MD, PhD, FIDSA, Washington University

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-125-L01-P

Disclosures:

G. Bolan, None

B. P. Stoner, None

G. Bolan, None

E. Hook III, Becton Dickinson: Consultant and Grant Investigator, Grant recipient and Speaker honorarium
Hologic/GenProbe: Research Contractor and Scientific Advisor, Consulting fee and Research support
Cepheid: Grant Investigator and Scientific Advisor, Grant recipient and Speaker honorarium

L. Manhart, Pfizer, Inc.: Recipient of study drugs, study drugs
Gen-Probe, Inc.: Recipient of test kits and reagents, test kits and reagents
Bio-Rad: Recipient of travel and conference support, Travel and conference support

K. Ghanem, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.